Clinical

Articles

Lilly’s Rezvoglar is a long-acting human insulin analog. It follows Semglee as a biosimilar that can be substituted for Lantus for both adults and children with diabetes.


FDA Approves Second Interchangeable Lantus Biosimilar 

Denise Myshko is your editorial contact for the Formulary Watch. She joined Formulary Watch as editor is June 2021 from Oncology Live. Prior to that, she was managing editor of PharmaVOICE, a trade publication in the pharmaceutical industry. Email: dmyshko@mjhlifesciences.com

Tzield addresses the underlying cause of the disease, where the immune system destroys the insulin producing cells in the pancreas. It will be available by the end of the year with a wholesale acquisition cost of $13,850 per vial.

FDA Approves First Drug that Delays Diabetes

Omnipod DASH PDMs are at increased risk of malfunction if overcharged beyond the maximum battery voltage.

Battery Issues Affect Omnipod Dash Personal Diabetes Managers

A new formulary design will be offered on the Value Script and Value Plus plans; it will contain medications used to treat diabetes and will cost only $11 per 30-day supply.

Wellcare Expands Medicare Drug Coverage, Adds Amazon as Preferred Pharmacy

Omnipod 5 is now available through retail pharmacies, as well as specialty and mail-order pharmacies.

FDA Expands Use of Omnipod 5 for Younger Children

Abiraterone is used together with prednisone to treat patients with metastatic prostate cancer.

CivicaScript Launches Generic Abiraterone 

The Inflation Reduction Act also allows Medicare to negotiate prices on some drugs and caps out-of-pocket costs for Medicare beneficiaries. 

Senate Passes Bill that Caps Insulin at $35 for Medicare Beneficiaries

Optum has teamed up with Sanofi to provide savings cards for six insulins through the Optum Store.

Optum to Offer $35 Insulin to Those without Insurance


The new PDUFA date is Nov. 17, 2022. If approved, teplizumab will be the first disease-modifying therapy for type 1 diabetes.


FDA Extends Review of Diabetes Therapy Teplizumab 

Sanofi has lowered the out-of-pocket cost for those without insurance of its insulins to $35 for a 30-day supply through the company’s savings program.

Diabetes and Endocrinology